Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects.

ABSTRACT: Triple negative breast cancer (TNBC) portraying deficient expression of estrogen receptor (ER), progesterone receptor (PR) and Human epidermal growth factor receptor 2 (HER2) is known to be the most aggressive subtype associated with poor prognosis and interventional strategies limited to chemotherapy and breast conserving surgery. Some TNBC incidences have also been reported with positive circ-HER2 expression thus rendering circ-HER2 a potential immunotherapy target to direct drug development. Resistance and recurrence reported with traditional approaches has led us towards the application of immunotherapeutic interventions owing to their anti-tumor efficacy. This review provides an elaborative insight on potential molecular biomarkers to be targeted by immunotherapy. Additionally, clinic

SUBMITTER: Khadela A 

PROVIDER: S-EPMC9751516 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature